Access cutting-edge lung cancer treatment through this clinical trial at a research site in Irvine. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Irvine at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
BH-30643-01 is a Phase 1/2, first-in-human, open label, dose escalation and expansion study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of
Sponsor: BlossomHill Therapeutics
Check if you qualify for this lung cancer clinical trial in Irvine, CA
If you're searching for lung cancer treatment options in Irvine, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Irvine research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.